Expanding the Horizon: Pioneering DART Bispecific Therapeutics in Areas Beyond Oncology
|
|
- Brendan Murphy
- 6 years ago
- Views:
Transcription
1 Expanding the Horizon: Pioneering DART Bispecific Therapeutics in Areas Beyond Oncology Paul Moore - VP, Immunology and Cell Biology MacroGenics, Inc. 7 th Annual World Bispecific Conference Boston Sept 29, 216
2 DART Bispecific Platform Highly robust bispecific platform Multiple applications across different disease areas Predictable manufacturability Long-term structural stability Ability to tailor half-life and valency Six DART molecules in clinical testing (1) Multiple pre-clinical programs advancing Significant validating DART collaborators Basic DART Crystallographic View (2) (1) Two clinical DART molecules are being developed by collaboration partners (MGD11/duvortuxizumab by Janssen and PF by Pfizer). (2) Crystallography of Pfizer s P-Cadherin x CD3 DART molecule. The two antigen binding sites (shown by red dot circles) are separated from each other by approximately 3 Å and are facing away from each other at an angle of approximately 9. Source: Root, et al., Antibodies 216, 5, 6; March 4, September 29, 216/Company Proprietary Information
3 DART: Designed for Broad Range of Modalities 3 September 29, 216/Company Proprietary Information
4 DART Formats Tailored for Different Applications Construct mab DART DART DART Specificity Monospecific Bispecific Bispecific Bispecific Valency Bivalent Bivalent Bivalent Tetravalent Half-life Days to weeks Hours Days to weeks Days to weeks Examples margetuximab, enoblituzumab, MGA12 MGD6 MGD7, MGD9, MGD1, MGD11 (duvortuxizumab), MGD14, PF MGD13 4 September 29, 216/Company Proprietary Information
5 MGD1: Application of DART for Receptor Coligation Coligation of an activating receptor (CD79B; BCR component) with an inhibitory receptor (CD32B) on the same human B cell Designed to block B cell activation in a nondepleting manner and to selectively target activated B cells Alternative to depletion-based strategies (Rituximab) or BLyS antagonists (Belimumab) Monovalent co-engagement of each target to favor avidity-driven binding selectivity to B cells 5 September 29, 216/Company Proprietary Information
6 CD32B and Its Involvement In Autoimmune Diseases Inhibitory regulator of both innate and adaptive immunity (only inhibitory FcgR) Expressed on leukocytes except for NK and T cells CD32B CD32B-KO mice fail to regulate humoral responses and develop lupus-like disease Checkpoint for B-cell activity maintaining humoral tolerance Allelic variant and expression level linked to autoimmune disease 6 September 29, 216/Company Proprietary Information
7 B Cell Normal Physiological Negative Feedback Loop Antigen B Cell Receptor (BCR) 3 CD79B 4 2 CD32B A hallmark of autoimmune disease is B cell reactivity and activation against Self antigens Uncontrolled B cell activation 1 normally prevented by triggering of negative feedback loop Via engagement of CD32B (FcɣRIIb) 2 ITAM ITIM Triggered when BCR recognizes immunecomplexed antigen 3 and concomitant engagement of CD32B by the Fc domain of the complex bound IgG 4 Inhibition of the activation signal This shuts down expansion and activation of B cells reactive to self antigens 1 B-cell activation 7 September 29, 216/Company Proprietary Information
8 Exploitation of Physiologic Inhibitory Pathway CD32B x CD79B DART-Mediated Negative Signaling Loop Antigen MGD1 recapitulates antigen driven proximity of activating (CD79B) and inhibitory (CD32B) receptors through co-ligation BCR CD79B CD32B ITAM ITIM B-cell activation Inhibition of the activation signal 8 September 29, 216/Company Proprietary Information
9 Anti-DART Anti-DART Anti-DART SSC CD19 Anti-DART MGD1: B-cell Specific Binding MGD1 Binds Selectively to Human B-cells B-cells Saturation Curve Binding to B-cells CD45 Monocytes CD3 NK-cells CD19 T-cells CD14 CD16 CD3 EC 1 =.22±.15 µg/ml EC 2 =.51±.22 μg/ml 9 September 29, 216/Company Proprietary Information
10 MGD1: Blocks B-cell Activation In Vitro Inhibition of BCR Activated Human B-cell Proliferation H -T d R (c p m ) H -T d R (c p m ) M G D 1 h Ig G 1 A n ti-c D 3 2 B m A b 5 M G D 1 A n ti-c D 7 9 B C o n tr o l D A R T A n ti-c D 3 2 B C o n tr o l D A R T C o n c e n tra tio n (n M ) C o n c e n tra tio n (n M ) Activity dependent on co-engagement of CD32B and CD79B 1 September 29, 216/Company Proprietary Information
11 . MGD1: Inhibition of Autoimmune Patient B-cell Activation PE-Texas Red-H: CD19 PE-Texas Red-H % In h ib itio n CD19 CD32B CD79B CD79B and CD32B expression on peripheral B-cells isolated from SLE patient APC-H: ch2b6 APC-H PE-Texas Red-H: CD19 PE-Texas Red-H PE-H: CD79b PE-H 1 In a c t iv e S L E ( n = 6 ) MGD1 ex-vivo inhibition of B-cells isolated from SLE patients with active or inactive disease status A c t iv e S L E ( n = 8 ) 11 September 29, 216/Company Proprietary Information
12 h Ig M (E L IS A,n g /m L ) MGD1: Blocks B-cell Activation In Vivo Experiments performed in mice engrafted with human PBMC (Xenogeneic GVHD) h Ig M higg Inhibition of Ig Secretion p =. 1 higg (ELISA,ng/mL) p=.24 MGD 1 dosed IV: 1 µg/animal, q3d 2wk Serum Analyses: Day 7 P B S M G D 1 PBS MGD1 1 Inhibition of GVHD Cumulative Survival (%) Days MGD1 (5. mg/kg) MGD1 (1. mg/kg) Rituximab (5. mg/kg) PBS MGD 1 dosed IV: q4d 9 12 September 29, 216/Company Proprietary Information
13 R a tio MGD1: Prolonged PK and Absence of B-cell Depletion Dose escalation of MGD1 in cross-reactive non-human Primate TK prolonged and dose linear Prolonged B-cell occupancy Pre-Rx Day 28 MGD1 Binding to B-cells post 1mg/kg dose B -c e ll/t -c e ll R a tio.6 No B-cell depletion V e h E n d D a y s 13 September 29, 216/Company Proprietary Information 13
14 MGD1: Inhibition of BCR Signaling Target Occupancy and Ex-vivo BCR Activation following 1 mg/kg MGD1 Target Occupancy Ex-vivo B-Cell Ca ++ Flux Assay Fluo-NW CD19 Fluo-NW Fluo-NW CD32B CD79B 15 GAH IgMµ- F(ab) 2 3 µg/ml Pre-Rx FL2-H: CD19 PE FL1-H: ch8b5 A488 FL2-H: CD19 PE FL4-H: CD79b APC 1 5 Pre-Rx Time (sec.) h 24 h FL2-H: CD19 PE FL2-H: CD19 PE FL1-H: ch8b5 A FL4-H: CD79b APB Time (sec.) Day 7 FL2-H: CD19 PE FL2-H: CD19 PE Day FL1-H: ch8b5 A FL4-H: CD79b APC September 29, 216/Company Proprietary Information Time (sec.)
15 MGD1: Phase 1A Study Design Enrolled healthy volunteers in six escalation cohorts Healthy volunteers represent homogeneous population to ascertain safety and pharmacodynamics effects of MGD1 Eight subjects to enroll at each dose cohort Six subjects were treated with MGD1 and two were treated with Placebo Staggered dosing at each dose cohort to assess safety & tolerability Randomized 6 subjects in double-blind manner after treating two sentinel subjects with MGD1 Subject 1: (MGD1) Subject 2: (MGD1) 24-hr Subjects 3-8: (4 MGD1; 2 Placebo) 24-hr R Dose Cohort MGD1 Dose (mg/kg) September 29, 216/Company Proprietary Information
16 MGD1: Phase 1A - Study Objectives Primary Objective Assess safety and tolerability of single dose of MGD1 in healthy adult subjects Secondary Objectives Evaluate single MGD1 dose pharmacokinetics Assess pharmacodynamics effects of MGD1 on humoral immune responses Evaluate potential anti-drug antibodies Exploratory Objectives Evaluate MGD1 binding to CD32B and CD79B on peripheral B cells Evaluate activation status of peripheral B cells and B-cell subsets Assess immune phenotype, including modulation of B-cell subsets Assess response of peripheral B cells to ex-vivo BCR stimulation 16 September 29, 216/Company Proprietary Information
17 C o n c e n t r a t i o n ( n g / m l ) % o f M a x B i n d i n g ( m e a n s e m ) MGD1: Human PK and Circulating B-cell Occupancy MGD1 Serum Levels B-cell Occupancy Days D a y s 6 h Days D a y s MGD1 Dosing: Placebo.1mg/kg.1mg/kg.3mg/kg 1 mg/kg 3 mg/kg 1 mg/kg MGD1 serum concentrations increase linearly with dose Half-life: ~8 days at 1mg/kg Maximum B-cell occupancy at doses 1 mg/kg Sustained receptor occupancy beyond one week at doses 1 mg/kg 17 September 29, 216/Company Proprietary Information
18 C e l l s / L ( m e a n s e m ) R a t i o ( m e a n s e m ) MGD1: No Evidence of B-cell Depletion Longitudinal Analyses of Peripheral Immune Cells Absolute B-cell Counts B/T Ratio h Days D a y s D a y s Placebo MGD1 Dosing:.1mg/kg.1mg/kg 1 mg/kg 3 mg/kg.3mg/kg 1 mg/kg 18 September 29, 216/Company Proprietary Information
19 S t i m u l a t e d B C e l l s / I o n o m y c i n ( m e a n s e m ) Treatment with MGD1 Inhibited B-Cell Activation R e la t i v e P e a k R e s p o n s e Relative Peak Response Placebo 1 mg/kg 3 mg/kg 1 mg/kg MGD1 Dosing Days s p<.1; p<.1 (Student s t-test compared to placebo) PBMCs from enrolled subjects collected longitudinally after MGD1 treatment Ca 2+ flux (hallmark of B-cell activation) induced ex vivo by B-cell receptor ligation using anti-igm Data normalized to maximum Ca 2+ permeability (maximum induction) via ionomycin Dose dependent B-cell inhibition demonstrated with increasing doses of MGD1 Inhibition sustained for several weeks at highest dose levels 19 September 29, 216/Company Proprietary Information
20 R e l a t i v e M F I ( % o f T i m e Z e r o, m e a n s e m ) % c h a n g e % c h a n g e R e l a t i v e M F I ( % o f T i m e Z e r o, m e a n s e m ) % c h a n g e MGD1 Modulated Cell Surface BCR and Serum Ig Levels CD27 - Naïve B Cells CD27 + Memory B Cells MGD1 Down-Regulation of Cell Surface Ig Expression migdm I g D Dose-dependent down modulation of cell surface BCR expression on both naïve and memory B cells Days D a y s miggm I g G Days a y s p<.5 (Paired t-test compared to baseline) MGD1 Modulation of Circulating Serum Ig Levels Serum S e r u m IIgG g G Days D a y s S e r u m I g M Placebo Serum IgM Days D a y s Serum S e r u m IIgA g A Days D a y s MGD1 Dosing: 1 mg/kg 3 mg/kg 1 mg/kg 2 September 29, 216/Company Proprietary Information
21 MGD1 Impacts Naïve & Mature B-cells Bone Marrow Periphery Stem Cell Pro B-cell Pre B-Cell Immature B-Cell Naïve B-Cell Mature B-Cell Cytoplasmic µ + Surface Surface Surface IgM + & IgD + IgM + & IgD + IgM+, IgG + & IgD + Memory B-Cell Surface IgG + & IgA + = CD32B = CD79B = Immunoglobulin Plasmablast Cytoplasmic IgM + Plasma Cell Cytoplasmic IgG + A single MGD1 dose: Modulates naïve and mature B-cell signal transduction via signaling blockade and/or down-regulation of surface Ig Decreases serum IgM levels, suggesting an impact on plasmablasts Lack of CD79B expression on plasma cells is consistent with no effect on other serum Ig 21 September 29, 216/Company Proprietary Information
22 M F I (m e a n S E M ) M F I (m e a n S E M ) MGD1 Mediates Reduction of B-cell CD4 Expression CD4 Expression C D 4 E x p r e s s i o n HLA-DR Expression H L A - D R E x p r e s s i o n h Days D a y s p<.5 (Paired t-test compared to baseline) 6 h 1 Placebo Days D a y s MGD1 Dosing: 1 mg/kg 3 mg/kg 1 mg/kg MGD1 has potential impact on B-cell : T-cell interactions Decreased cell surface expression of CD4, a B cell co-stimulatory molecule No effect on other cell surface markers observed HLA-DR (as shown), CD8/86, CD69, CD25 22 September 29, 216/Company Proprietary Information
23 Summary of Phase 1a Clinical Experience MGD1 is well tolerated as single dose up to 1 mg/kg in healthy subjects No B-cell activation or cytokine release No depletion of peripheral B cells Peripheral B-cells saturated at 1mg/kg dose levels with sustained receptor occupancy with increasing doses MGD1 down-modulated B-cell function at multiple levels Reduction in BCR-induced Ca2+ mobilization Decreased surface Ig expression both naïve and memory B-cells Decreased serum IgM levels, suggesting an impact on plasmablasts Data supports continued development of MGD1 in patients with autoimmune disorders 23 September 29, 216/Company Proprietary Information
24 DART Platform Applications in HIV Cure Challenge Proposed Strategy Current combination antiretroviral therapy (cart) cannot eradicate HIV infection Latency: the presence of integrated but transcriptionally quiet proviral DNA, primarily within central memory T cell population, makes the infected cells invisible to immune system Chronically infected individuals generally experience rapid viral rebound after cart interruption (usually within weeks) Latency-reversing agent (LRA) to reactivate HIV antigen expression Shock-and-Kill lysis Env Goal CD3 To reduce or eliminate HIV latent reservoirs T cells 24 September 29, 216/Company Proprietary Information
25 L U M (R L U ) T u m o r V o lu m e (m m 3 ) R a n d o m. P B M C s T u m o r C e lls DART: Potent T-cell mediated Target Cell Elimination Example: MGD11 (CD19 x CD3) 3 V e h ic le 2 5 C o n t r o l D A R T (.5 m g / k g ) A v g T u m o r V o l m m 3 A v g T u m o r V o l m m 3 L a r g e r T u m o r G r o u p S m a lle r T u m o r G r o u p Anti-Tumor Activity R x Treatment of B-cell lymphoma (HBL-2) in human T-cell reconstituted mice Redirected T-cell Killing CD19+Raji + PBMC (E:T = 31:1) M G D 1 1 C D 1 9 -B it E C o n tro l M P 3 D A R T Inguinal Lymph Node Mandibular Lymph Node, Spleen CD2 CD2 CD2 CD2 Profound B-cell Depletion in Lymphoid Organs (NHP) C o n c e n tra tio n (n M ) Liu et al., 216 Clinical Cancer Research (In press) Control MGD11 25 September 29, 216/Company Proprietary Information 25
26 Broadly Reactive Anti-Env Antibodies and Their Targets Mature Env trimer V1-V2 loop PGT145 CD4-binding site VRC1 C1-C4 (gp12 cluster A) A32 Glycan-V3 loop PGT121 gp41 cluster I 7B2 Broadly Neutralizing PGT121 PGT145 VRC1 1E8 gp41 MPER 1E8 Non-Neutralizing, ADCC-mediating A32 7B2 Adapted from Euler Front Immunol 212 Variant Env structures (legitimate targets on infected cells) Mature trimer Uncleaved gp16 trimer gp41 stump (gp12 shedding) Alternate trimer gp12/gp41 monomers 26 September 29, 216/Company Proprietary Information
27 HIV X CD3 Molecules Mediate Potent CTL Activity Env+ Jurkat-522 F/Y cells (targets), pan-t-cells (effectors), cytolysis by LDH release assay EC5 ~15 pg/ml (~3 pm) Sung et al. 215 J Clin Invest 27 September 29, 216/Company Proprietary Information
28 DART Molecule-mediated CTL Activity Against HIV-Infected CD4+ Cells Resting CD4+ T cells infected with HIV-1; CD8+ T cells (E:T 2:1); assay p24+ CD4+ cells HIV-1 RW/92/8 (subtype A) HIV-1 BaL (subtype B) HIV-1 IN/93/95 (subtype C) High potency HIV DARTs A32, 7B2, PGT121, PGT145 Low potency HIV DARTs VRC1, 1E September 29, 216/Company Proprietary Information Sloan et al. 215 PLOS Pathogens
29 HIV Clearance in Resting CD4 Cells Reactivated By LRA HIV pt on ART PBMC Resting CD4 + cells, culture with ARVs (24h) CD8 + cells + VOR (6h) ± DART (24-96h) E:T = 1:1 Allogeneic HIV - donor cells to amplify virus (15 days) p24+ wells (QVOA) HIV DART molecule-mediated virus clearance in 4 of 4 patients (longer time needed for Pt 795) September 29, 216/Company Proprietary Information Sung et al. 215 J Clin Invest
30 MGD14: HIV x CD3 DART Candidate Targeted Indication Development Partner Humanized HIV x CD3 Fc-bearing DART (extended PK) HIV arm based on a broadly reactive, ADCC-mediating, nonneutralizing anti-env antibody Elimination of latent HIV infection in combination with latencyreversing agents and anti-retroviral therapy (ART) Preclinical activities ongoing Initial GMP production completed IND targeted for 1H:217 MacroGenics retains worldwide commercial rights Funded through NIAID (NIH) contract awarded 9/15/15 In collaboration with Duke/UNC 3 September 29, 216/Company Proprietary Information
31 MG Pipeline of Product Candidates Clinical-stage programs Program (Target) Indication Pre-IND Phase 1 Phase 2 Phase 3 Partner Our Commercial Rights ONCOLOGY margetuximab (HER2) Breast (HER2+) SOPHIA Green Cross Worldwide, except Breast (low HER2) South Korea Gastric (+pembrolizumab) enoblituzumab (B7-H3) Solid Tumors (mono.) Worldwide Solid Tumors (+ipi.) Solid Tumors (+pembro.) MGD6 (CD123 x CD3) AML/MDS Servier North America, Japan, South Korea, India MGD7 (gpa33 x CD3) Colorectal MGD11 (CD19 x CD3) B-cell Malignancies Janssen U.S. Co-promote MGD9 (B7-H3 x CD3) Solid Tumors Worldwide MGA12 Solid Tumors/Heme Worldwide MGD13 (PD-1 x LAG-3) Solid Tumors/Heme Worldwide AUTOIMMUNE & INFECTIOUS DISEASES teplizumab (CD3) Type 1 Diabetes Prev. NIDDK/NIH Worldwide MGD1 (CD32B x CD79B) Autoimmune Disorders Worldwide MGD14 (HIV x CD3) HIV NIAID/NIH Worldwide MacroGenics has option to fund late-stage development in exchange for U.S. and Canada profit share. DART mab 31 September 29, 216/Company Proprietary Information
What is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationImmunobiology 7. The Humoral Immune Response
Janeway Murphy Travers Walport Immunobiology 7 Chapter 9 The Humoral Immune Response Copyright Garland Science 2008 Tim Worbs Institute of Immunology Hannover Medical School 1 The course of a typical antibody
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationImpact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir
Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationAdaptive Immunity: Humoral Immune Responses
MICR2209 Adaptive Immunity: Humoral Immune Responses Dr Allison Imrie 1 Synopsis: In this lecture we will review the different mechanisms which constitute the humoral immune response, and examine the antibody
More informationImmunology - Lecture 2 Adaptive Immune System 1
Immunology - Lecture 2 Adaptive Immune System 1 Book chapters: Molecules of the Adaptive Immunity 6 Adaptive Cells and Organs 7 Generation of Immune Diversity Lymphocyte Antigen Receptors - 8 CD markers
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationGeneration of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells
Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells T. Matt Holl 1, Masayuki Kuraoka 1, Dongmei Liao 1, Laurent Verkoczy 2, M. Anthony Moody 2, Munir
More informationchapter 17: specific/adaptable defenses of the host: the immune response
chapter 17: specific/adaptable defenses of the host: the immune response defense against infection & illness body defenses innate/ non-specific adaptable/ specific epithelium, fever, inflammation, complement,
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationCorporate Overview November 2017
Corporate Overview November 2017 The information in this slide deck is current as of, unless otherwise noted. The information in this slide deck is qualified in its entirety by reference to MacroGenics
More informationAdaptive Immune System
Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationDefensive mechanisms include :
Acquired Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated immunity Humoral immunity Two mechanisms 1) Humoral
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationB cell activation and antibody production. Abul K. Abbas UCSF
1 B cell activation and antibody production Abul K. Abbas UCSF 2 Lecture outline B cell activation; the role of helper T cells in antibody production Therapeutic targeting of B cells 3 Principles of humoral
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationDual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast NALM-6 tumor cells (B-ALL) Human macrophages
Dual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast Krzysztof Masternak, PhD, Head of Biology 1 2 nd Biologics & BOARD Biosimilars MEETING Congress MARCH 2012 NALM-6
More informationBlood and Immune system Acquired Immunity
Blood and Immune system Acquired Immunity Immunity Acquired (Adaptive) Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationThe T cell receptor for MHC-associated peptide antigens
1 The T cell receptor for MHC-associated peptide antigens T lymphocytes have a dual specificity: they recognize polymporphic residues of self MHC molecules, and they also recognize residues of peptide
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationIdentification of novel immune regulators of tumor growth using highthroughput
Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More information2014 Pearson Education, Inc. Exposure to pathogens naturally activates the immune system. Takes days to be effective Pearson Education, Inc.
The innate immune interact with the adaptive immune system 1. Damage to skin causes bleeding = bradykinin activated, resulting in inflammation 2. Dendritic phagocytose pathogens Adaptive immunity 4. Dendritic
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationThe Adaptive Immune Response. B-cells
The Adaptive Immune Response B-cells The innate immune system provides immediate protection. The adaptive response takes time to develop and is antigen specific. Activation of B and T lymphocytes Naive
More informationVMC-221: Veterinary Immunology and Serology (1+1) Question Bank
VMC-221: Veterinary Immunology and Serology (1+1) Objective type Questions Question Bank Q. No. 1 - Fill up the blanks with correct words 1. The British physician, who developed the first vaccine against
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationAdaptive Immunity: Specific Defenses of the Host
17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function
More informationMon, Wed, Fri 11:00 AM-12:00 PM. Owen, Judy, Jenni Punt, and Sharon Stranford Kuby-Immunology, 7th. Edition. W.H. Freeman and Co., New York.
Course Title: Course Number: Immunology Biol-341/541 Semester: Fall 2013 Location: HS 268 Time: Instructor: 8:00-9:30 AM Tue/Thur Dr. Colleen M. McDermott Office: Nursing Ed 101 (424-1217) E-mail*: mcdermot@uwosh.edu
More informationInduction and Clearance of Latent HIV Infection:
214 Towards an HIV Cure symposium Melbourne Induction and Clearance of Latent HIV Infection: an Ex-Vivo Assessment of Immune Effectors using Cells from ART-treated Patients DM Margolis 1, C Garrido 1,
More informationFor questions 1-5, match the following with their correct descriptions. (24-39) A. Class I B. Class II C. Class III D. TH1 E. TH2
Questions Made by SI ATTENDEES!! :) Page 1 of 6 Student-Made Practice Exam Activity All questions, answers, and slide numbers are based off of Monday s SI activity, where students/attendees created possible
More informationThere are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell
There are 2 major lines of defense: Non-specific (Innate Immunity) and Specific (Adaptive Immunity) Photo of macrophage cell Development of the Immune System ery pl neu mφ nk CD8 + CTL CD4 + thy TH1 mye
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationReprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationGBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS
GBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS JONATHAN BACK 1 ; MARTIN WERMKE 2 ; JULIE MACOIN 1 ; AMELIE CROSET 1 ; JOHN KAUH 3 ; VENKATESHWAR REDDY
More informationAdaptive Immunity. Lecture 14 Biology W3310/4310 Virology Spring Life is simple, but we insist on making it complicated CONFUCIUS
Adaptive Immunity Lecture 14 Biology W3310/4310 Virology Spring 2016 Life is simple, but we insist on making it complicated CONFUCIUS Host defenses Intrinsic - Always present in the uninfected cell - Apoptosis,
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationChapter 23 Immunity Exam Study Questions
Chapter 23 Immunity Exam Study Questions 1. Define 1) Immunity 2) Neutrophils 3) Macrophage 4) Epitopes 5) Interferon 6) Complement system 7) Histamine 8) Mast cells 9) Antigen 10) Antigens receptors 11)
More informationWhite Blood Cells (WBCs)
YOUR ACTIVE IMMUNE DEFENSES 1 ADAPTIVE IMMUNE RESPONSE 2! Innate Immunity - invariant (generalized) - early, limited specificity - the first line of defense 1. Barriers - skin, tears 2. Phagocytes - neutrophils,
More informationAdaptive immunity. Adaptive Immunity. Principles of immune defense. Adaptive immunity. against extracellular or intracellular pathogens
Principles of immune defense Toxicology Course Vienna MODULE 12 Immunotoxicology, Allergy July 2, 2008 Prof. Erika Jensen-Jarolim, MD Dept. of Pathophysiology Medical University Vienna Gastrointestinaltrakt:
More informationMerus. Corporate Presentation. November 15, 2018
Merus Corporate Presentation November 15, 2018 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationThe Lymphatic System and Body Defenses
PowerPoint Lecture Slide Presentation by Patty Bostwick-Taylor, Florence-Darlington Technical College The Lymphatic System and Body Defenses 12PART B Adaptive Defense System: Third Line of Defense Immune
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationIAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal
IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal Marcus Altfeld Professor of Medicine Outline Immune recognition of HIV-1-infected cells Kinetics of antigen
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationCELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.
!! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)
More informationThe Immune System. by Dr. Carmen Rexach Physiology Mt San Antonio College
The Immune System by Dr. Carmen Rexach Physiology Mt San Antonio College What is the immune system? defense system found in vertebrates Two categories Nonspecific specific provides protection from pathogens
More informationChapter 17B: Adaptive Immunity Part II
Chapter 17B: Adaptive Immunity Part II 1. Cell-Mediated Immune Response 2. Humoral Immune Response 3. Antibodies 1. The Cell-Mediated Immune Response Basic Steps of Cell-Mediated IR 1 2a CD4 + MHC cl.
More informationLESSON 2: THE ADAPTIVE IMMUNITY
Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike
More informationUnit 5 The Human Immune Response to Infection
Unit 5 The Human Immune Response to Infection Unit 5-page 1 FOM Chapter 21 Resistance and the Immune System: Innate Immunity Preview: In Chapter 21, we will learn about the branch of the immune system
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationAntigen-Independent B-Cell Development Bone Marrow
Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on
More informationImmune system. Self/non-self recognition. Memory. The state of protection from infectious disease. Acceptance vs rejection
Immune system The state of protection from infectious disease Self/non-self recognition 自我 非我 Acceptance vs rejection Memory 疫苗 2 Microbes Commensal Microbes 共生菌 Normal flora: usually confined to certain
More information1. Specificity: specific activity for each type of pathogens. Immunity is directed against a particular pathogen or foreign substance.
L13: Acquired or adaptive (specific) immunity The resistance, which absent at the time of first exposure to a pathogen, but develops after being exposed to the pathogen is called acquired immunity. It
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationFoundations in Microbiology
Foundations in Microbiology Fifth Edition Talaro Chapter 15 The Acquisition of Specific Immunity and Its Applications Chapter 15 2 Chapter Overview 1. Development of the Dual Lymphocyte System 2. Entrance
More informationEngineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure
Engineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure Zoë Wallace Nuffield Dept. of Medicine University of Oxford 23 rd Annual Conference of the British HIV Association The HIV Reservoir
More informationDesigning clinical trials with BiTE antibody constructs by leveraging from nonclinical data. Benno Rattel Biologics Congress Berlin, 2015
Designing clinical trials with BiTE antibody constructs by leveraging from nonclinical data Benno Rattel Biologics Congress Berlin, 215 1 BiTE Antibody Contructs are Designed to Function as a Bridge between
More informationImmunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard
More informationAdaptive immune responses: T cell-mediated immunity
MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,
More informationTest Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas
Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas Chapter 04: Antigen Recognition in the Adaptive Immune System Test Bank MULTIPLE CHOICE 1. Most T lymphocytes
More informationModule R: Recording the HIV Reservoir
Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationChapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!
MCMP422 Immunology and Biologics Immunology is important personally and professionally! Learn the language - use the glossary and index RNR - Reading, Note taking, Reviewing All materials in Chapters 1-3
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationImmunology. Overview. Kris.ne Kra1s, M.D.
Immunology Overview Kris.ne Kra1s, M.D. Immunology Overview Defini.ons Cells Lymphocytes An.gen-presen.ng cells Effector cells Responses The innate immune response Capturing and displaying an.gens Cell-mediated
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationJefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More informationThe potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,
More informationPhysiology Unit 3. ADAPTIVE IMMUNITY The Specific Immune Response
Physiology Unit 3 ADAPTIVE IMMUNITY The Specific Immune Response In Physiology Today The Adaptive Arm of the Immune System Specific Immune Response Internal defense against a specific pathogen Acquired
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationDeveloping Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014
Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic Kevin G. McLure, PhD EpiCongress July 2014 Zenith Epigenetics Overview Formed from Resverlogix as an independent
More informationAll animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
More informationChapter 24 The Immune System
Chapter 24 The Immune System The Immune System Layered defense system The skin and chemical barriers The innate and adaptive immune systems Immunity The body s ability to recognize and destroy specific
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationAdvances in Cancer Immunotherapy
Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain
More information